Clinical oncology evidence, translated into treatment decisions.
OncLive On Air is a clinical oncology education show built around educational symposia, tumor board excerpts, and focused conversations. Its strongest episodes move from trial design and endpoints to the harder bedside question: how evidence should shape treatment choices.
PRESS PLAY
OncLive On Air is a technical oncology education show built for the space between published evidence and day-to-day treatment decisions. The format shifts between educational symposium excerpts, tumor board excerpts, clinical discussion, and structured clinical teaching. It is not a broad wellness show. It is aimed at people who want to hear oncologists reason through disease settings, trial designs, endpoints, biomarkers, toxicities, and patient-selection questions. The pace is measured. The vocabulary is clinical. Head and neck cancer coverage follows immunotherapy added to chemoradiation, larynx preservation tradeoffs, surgical versus nonsurgical treatment, and neoadjuvant combinations. Cutaneous squamous cell carcinoma episodes compare PD-1 and PD-L1 inhibition while acknowledging transplant status, immune suppression, injectable approaches, compassionate access, and reimbursement realities. Breast cancer episodes carry much of the show’s center of gravity. They examine recurrence scores, adjuvant chemotherapy, CDK4-6 inhibitors, checkpoint inhibitors, HER2-directed maintenance therapy, T-DXd, TROP2 therapies, genetic testing, BRCA-related decisions, prophylactic mastectomy, intensive screening, and survivorship care. Small cell lung cancer coverage turns toward extensive-stage disease, bispecific T-cell engagers, antibody drug conjugates, and drug-specific toxicities. The show’s editorial value comes from its patience with nuance. Speakers do not simply name a drug and move on. They circle eligibility criteria, compare trial populations, test assumptions against patient comorbidities, and return to the practical question of who should receive which treatment, and when. Some episodes are plainly symposium-derived, with occasional repetition and sponsor framing, but the clinical substance usually sits close to active practice debates. It is particularly useful for oncology professionals, medical educators, fellows, and specialized listeners who want a current map of how cancer treatment conversations are evolving across tumor types.
Made for: Healthcare professionals, oncology clinicians, trainees, medical educators, and highly informed health listeners who are comfortable with trial data and treatment terminology. It best suits people looking for practice implications rather than general cancer explainers.
What sets it apart: The show stays close to the decision-making layer of oncology, where trial endpoints, biomarkers, surgical options, toxicity risks, and patient factors have to be reconciled. Its symposium and panel format gives the discussions a practical, case-facing texture.
Based on 5 episodes we listened to · September 2026
Detailed oncology conversations connect clinical trial evidence with treatment choices, multidisciplinary tradeoffs, and the financial burden carried by patients.
OncLive On Air puts cancer treatment decisions under pressure, using educational symposium excerpts and specialist conversations to test emerging evidence against clinical practice.
Clinical trial acronyms arrive fast; you stay for the treatment decisions hiding behind them.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A practical look at locally advanced head and neck cancer trials and the tradeoffs around larynx preservation.
This episode follows Barbara Burtness and Quinn Lee as they weigh recent and ongoing trials in locally advanced head and neck cancer, with immunotherapy and larynx preservation at the center of the discussion.
A careful look at PD-1 and PD-L1 choices in advanced cutaneous squamous cell carcinoma.
This episode keeps its focus on PD-L1 inhibition in advanced cutaneous squamous cell carcinoma, then turns to the practical question of how PD-L1 fits beside PD-1 blockade. Dr.
A focused clinical review of how TDXD may fit into early-stage HER2-positive breast cancer care.
This PlayNext review follows a focused oncology debate on where TDXD belongs in early-stage HER2-positive breast cancer care, using Destiny Breast 11, Destiny Breast 05, and a 45-year-old woman's right-breast mass as the frame.
A focused, technical review of how genetic risk informs breast cancer testing, surgery, screening, and treatment.
Breast cancer care is framed as a sequence of choices that begins with genetic testing and extends into surgery, screening, and drug treatment. Drs. Don D.
A clear, measured look at how insurance type, out-of-pocket costs, and lost wages can shape gynecologic cancer care.
Financial toxicity lands here as a real part of gynecologic cancer care, not a side issue. Dr. Ursula Matalonis and Dr. Katherine Esselin look at how out-of-pocket costs, insurance type, bad debt write-offs, and lost wages can change the experience of treatment.
Local medicine, told through physicians' lives.
Neurology evidence, translated for clinical judgment.
Barbara Burtness and Quinn Lee anchor the discussion.
Drs.
This episode discusses redefining adjuvant strategies for early hormone receptor-positive HER2-negative breast cancer, focusing on genomic assays, chemotherapy, and CDK4-6 inhibitors based on clinical trials like TAYLOR-X.
This episode reviews recent Phase III clinical trials like PATINA and HER2 CLIMO5 to discuss frontline and maintenance therapy strategies for HER2+ metastatic breast cancer.
This podcast discusses new treatment approaches for extensive stage small cell lung cancer, focusing on bispecific T-cell engagers and antibody drug conjugates, based on data presented at an educational symposium.
TDXD takes center stage in a focused discussion of early-stage HER2-positive breast cancer.
The program examines how genetic testing can shape breast cancer management.
OncLive On Air features Dr.
This episode discusses the transformative T-DXd trials for HER2-positive breast cancer, featuring an interview with Dr.
This episode features Drs.
This episode features Drs.